title: Differences in functional activity and antigen expression of granulocytes primed in vivo with filgrastim, lenograstim, or pegfilgrastim.
abstract: BACKGROUND
  Granulocyte-colony-stimulating factor (G-CSF) is known to affect functional activity and antigen expression of neutrophil granulocytes. Beside nonglycosylated filgrastim and glycosylated lenograstim, pegylated filgrastim (pegfilgrastim) has recently been introduced for single administration into clinical use.
  
  
  METHODS
  Here, granulocytes from 27 patients with nonmyeloid malignancies were compared functionally (migration, reactive oxygen species production, and G-CSF serum levels) and phenotypically (cell surface antigen expression) before and after G-CSF administration.
  
  
  RESULTS
  After exposure to G-CSF, chemotaxis was reduced significantly in the filgrastim group. Immunophenotypically, in vivo G-CSF-primed granulocytes were more mature in the lenograstim than in the filgrastim and to lesser extent in the pegfilgrastim groups as shown by the expression profile for CD11b, CD14, and CD16. Of note, G-CSF serum levels were similar among the groups.
  
  
  CONCLUSIONS
  Our data suggest that granulocytes exposed to glycosylated G-CSF in vivo seem to resemble more closely their steady-state phenotype than after treatment with nonglycosylated and to lesser extent pegylated G-CSF.
authors.affiliation: Department of Internal Medicine V, University of Heidelberg, German Cancer Research Center, Heidelberg, Germany.
authors.forename: Daniel
authors.initials: D
authors.lastname: Ribeiro
authors.forename: Marlon R
authors.initials: MR
authors.lastname: Veldwijk
authors.forename: Axel
authors.initials: A
authors.lastname: Benner
authors.forename: Stephanie
authors.initials: S
authors.lastname: Laufs
authors.forename: Frederik
authors.initials: F
authors.lastname: Wenz
authors.forename: Anthony D
authors.initials: AD
authors.lastname: Ho
authors.forename: Stefan
authors.initials: S
authors.lastname: Fruehauf
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000097:blood; D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000096:biosynthesis*; D002633:Chemotaxis / Q000187:drug effects*; D005260:Female; D000069585:Filgrastim; D005786:Gene Expression Regulation / Q000187:drug effects*; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage* / Q000097:blood; D006801:Humans; D000078224:Lenograstim; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000473:pathology; D009504:Neutrophils / Q000378:metabolism* / Q000473:pathology; D011092:Polyethylene Glycols; D017382:Reactive Oxygen Species / Q000378:metabolism; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000097:blood
chemical_list: D000276:Adjuvants, Immunologic; D015703:Antigens, CD; D017382:Reactive Oxygen Species; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; C455861:pegfilgrastim; D011092:Polyethylene Glycols; D000078224:Lenograstim; D000069585:Filgrastim